Therapeutic AreaFormulary ChoicesCost for 28
(unless otherwise stated)
Rationale for decision / comments
7.3 Contraceptives
Women requiring contraception should be given information about and offered a choice of all methods including LARC (long-acting reversible contraception).
Interactions

The effectiveness of combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, and vaginal rings can be considerably reduced by interaction with drugs that induce hepatic enzyme activity (e.g. carbamazepine, eslicarbazepine, modafinil, nelfinavir, nevirapine, oxcarbazepine, phenytoin, phenobarbital, primidone, ritonavir, St John’s Wort, topiramate, and, above all, rifabutin and rifampicin).

Hormonal contraceptives and antibacterials that do not induce liver enzymes

Advice on interactions between combined hormonal contraceptives and antibacterials that do not induce liver enzymes has been updated to take into account the recommendations of the Faculty of Sexual and Reproductive Healthcare Clinical Guidance: Drug Interactions with Hormonal Contraception (January 2011).

Additional contraceptive precautions are no longer necessary when antibacterials that do not induce liver enzymes are taken with combined oral contraceptives, (unless diarrhoea or vomiting occurs), contraceptive patches or vaginal rings. Click here for more information.

Some other interactions of hormonal contraceptives have been updated in Appendix 1 of the BNF: Interactions (under Oestrogens and Progestogens)
7.3.1 Combined hormonal contraceptives
Low strengthEthinylestradiol / norethisterone
as Loestrin 20®
20mcg/1mg tablets: £2.30 (63)
Ethinylestradiol / drospirenone
as Eloine®
20mcg/3mg tablets: £14.70 (84)
Standard strength:Ethinylestradiol / norgestrel
asRigevidon®
as Ovranette®
30mcg/150mcg tablets: £1.89 (63)
30mcg/150mcg tablets: £2.20 (63)
Rigevidon® is a cost-effective alternative to Microgynon 30® and Ovranette®.
Ethinylestradiol / norgestimate
as Cilest®
as Cilique®
as Lizinna®
35mcg/250mcg tablets: £7.16 (63)
35mcg/250mcg tablets: £4.65 (63)
35mcg/250mcg tablets: £5.37 (63)
Ethinylestradiol / gestodene
as Millinette® 20/75
as Millinette® 30/75
20mcg/75mcg tablets: £5.41 (63)
30mcg/75mcg tablets: £4.12 (63)

NB: Third-generation COCs containing the progestogens gestodene or desogestrel (e.g. Femodene®) are associated with a higher risk of VTE.
Millinette® 30/75 is a cost-effective alternative to Femodene®
Ethinylestradiol / norethisterone (tri phasic) as Tri-Novum® 35mcg/500mcg,
35mcg/750mcg, &
35mcg/1mg: £3.46 (63)
Ethinylestradiol / drospirenone
as Lucette®
as Dretine®
as Yacella®
30mcg/3mg: £9.35 (63)
30mcg/3mg: £8.30 (63)
30mcg/3mg: £8.30 (63)
Cost effective equivalent to Yasmin®
7.3.2 Progestogen-only contraceptives (POPs)Norethisterone 350mcgTablets: £4.50 (84)

Progestogens gestodene or desogestrel (e.g. Cerelle® ) are associated with a higher risk of VTE.
7.3.2.3 Intra uterine POP systemMirena®



Jaydess®



Levosert®
T-shaped plastic frame levonorgestrel 20 micrograms/24 hours, net price = £88.00. Replace after 5 years


13.5mg: £69.22. Replace after 3 years


52mg T-shaped intrauterine system (releasing approx 20 microgram/24 hrs), 1=£66.00.Replace after 4 years
Five year use license



Smaller frame and smaller reservoir. Approved for use in the CASH service where a coil is appropriate but Mirena is not suitable or not tolerated. Three year life license. Contraception only
Long-acting reversible contraception
(LARC)
LARC methods are more cost-effective than COC pill even at one year.
Please see NICE guidance on Features of the larc methods to discuss with women (Sept 14) and Choice of method for different groups of women (Sept 14)
Medroxy-progesterone
as Depo-Provera®

Medroxy-progesterone
as Sayana Press®
150mg/ml prefilled syringe: £6.01 (1)


104mg/0.65ml susp in pre-filled injector, 1=£6.90.
Etonogestrel
as Nexplanon®
68mg implant: £83.43Nexplanon® is bioequivalent to Implanon® (discontinued); it has the same release rate and 3-year duration of action. Nexplanon® also has a different application device and insertion technique. Please visit http://www.nexplanontraining.co.uk/ or contact SDM directly for training.
7.3.5 Emergency Hormonal Contraception (EHC)Levonorgestrel 1500mcg tablet
as Upostelle®
1500mcg tablet: £3.75 (1) Available via PGD through many pharmacies across Somerset, free of charge to all.
Levonorgestrol 1500mcg is the first-line oral preparation for patients presenting within 72 hours of UPSI or contraceptive failure.
DO NOT PRESCRIBE AS THE OTC PREPARATION: Levonelle One Step® (as over twice the cost of the POM product.)
Ulipristal acetate 30mg tablet ▼
as EllaOne®
30mg tablet: £14.05 (1)Patients presenting between 72 hours and 120 hours may be offered the choice of ulipristal acetate or intrauterine device and the risks and benefits of each method should be discussed with the patient.
Ulipristal is licensed for emergency contraception within 120 hours (5 days) after unprotected sexual intercourse (UPSI).
Pregnancy should be excluded before ulipristal is taken.
Please note that patients who have a BMI >26 or are greater than 70kg may require more than the standard 1.5mg dose of levonorgestrel.
Consider double dose (3mg) or CI-IUD or ulipristal.Link

Women taking enzyme inducing medication may require further measures. EC providers should advise women using enzyme-inducing drugs that the
effectiveness of UPA-EC and LNG-EC could be reduced.

Women requiring EC who are using enzyme-inducing drugs should be offered a Cu-IUD if appropriate. A 3 mg dose of LNG can be considered but women should
be informed that the effectiveness of this regimen is unknown. A double-dose of UPA-EC is not recommended.
Link to FSRH guideline
Pre-operative treatment of uterine fibroids Ulipristal acetate 5mg tablet
as Esmya®
5mg tablet: £ 114.13 (28)EMA Esmya: new measures to minimise risk of rare but serious liver injury.
Changed from AMBER drug to RED drug by Somerset Prescribing Forum (Mar 18).
The emergency contraceptive ellaOne also contains ulipristal acetate (single-dose, 30mg). No cases of serious liver injury have been reported with ellaOne and there are no concerns with this medicine at this time.